Three new mutations in hereditary nonpolyposis colorectal cancer (Lynch syndrome II) in Uruguay

Carlos Sarroca, Päivi Peltomäki, Nora Alfano, Gladys Tedesco, Adriana Della Valle, Alejandra Dominguez, Henry T. Lynch

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is the most common hereditary form of colorectal cancer (CRC). Our purpose is to describe three extended HNPCC families, each of which manifests novel germline mutations in Uruguay, a small country that is a study model for cancer investigation given its high cancer incidence and mortality rate. This is a study of three extended HNPCC families in which extensive genealogic information, medical history, and pathology findings are critically reviewed. DNA testing was performed for evidence of HNPCC mutations. The findings reveal three novel germline mutations, namely MLH1, with a deletion resulting in a frameshift and a premature stop codon (codon 228) in one of the families; in the second family, MSH2 exon 1, codon 61 at nucleotide 181, which results in immediate stop of translation; and in the third family, a mutation in MSH2 at exon 3: the amino acid at nucleotide 530, codon 117, causing a frameshift and a premature stop codon eight base pairs later. We conclude that it is important to study HNPCC mismatch repair genes because of emerging evidence for genotypic and phenotypic heterogeneity, which will harbor the potential to eventually translate this knowledge into specific screening and management protocols. Future projections for such mutations could even contribute to the emergence of molecular-based designer drugs developed through advances in genomics, proteomics, high-throughput screening, and bioinformatics, which would be effective therapeutically for these high-cancer risk patients.

Original languageEnglish
Pages (from-to)13-20
Number of pages8
JournalCancer Genetics and Cytogenetics
Volume142
Issue number1
DOIs
StatePublished - Apr 1 2003

Fingerprint

Lynch Syndrome II
Uruguay
Hereditary Nonpolyposis Colorectal Neoplasms
Mutation
Codon
Germ-Line Mutation
Nonsense Codon
Exons
Nucleotides
Designer Drugs
Neoplasms
DNA Mismatch Repair
Genomics
Computational Biology
Base Pairing
Proteomics
Colorectal Neoplasms
Pathology
Amino Acids
Mortality

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Three new mutations in hereditary nonpolyposis colorectal cancer (Lynch syndrome II) in Uruguay. / Sarroca, Carlos; Peltomäki, Päivi; Alfano, Nora; Tedesco, Gladys; Della Valle, Adriana; Dominguez, Alejandra; Lynch, Henry T.

In: Cancer Genetics and Cytogenetics, Vol. 142, No. 1, 01.04.2003, p. 13-20.

Research output: Contribution to journalArticle

Sarroca, Carlos ; Peltomäki, Päivi ; Alfano, Nora ; Tedesco, Gladys ; Della Valle, Adriana ; Dominguez, Alejandra ; Lynch, Henry T. / Three new mutations in hereditary nonpolyposis colorectal cancer (Lynch syndrome II) in Uruguay. In: Cancer Genetics and Cytogenetics. 2003 ; Vol. 142, No. 1. pp. 13-20.
@article{38b2893924134a649a6bea83a79f8dd5,
title = "Three new mutations in hereditary nonpolyposis colorectal cancer (Lynch syndrome II) in Uruguay",
abstract = "Hereditary nonpolyposis colorectal cancer (HNPCC) is the most common hereditary form of colorectal cancer (CRC). Our purpose is to describe three extended HNPCC families, each of which manifests novel germline mutations in Uruguay, a small country that is a study model for cancer investigation given its high cancer incidence and mortality rate. This is a study of three extended HNPCC families in which extensive genealogic information, medical history, and pathology findings are critically reviewed. DNA testing was performed for evidence of HNPCC mutations. The findings reveal three novel germline mutations, namely MLH1, with a deletion resulting in a frameshift and a premature stop codon (codon 228) in one of the families; in the second family, MSH2 exon 1, codon 61 at nucleotide 181, which results in immediate stop of translation; and in the third family, a mutation in MSH2 at exon 3: the amino acid at nucleotide 530, codon 117, causing a frameshift and a premature stop codon eight base pairs later. We conclude that it is important to study HNPCC mismatch repair genes because of emerging evidence for genotypic and phenotypic heterogeneity, which will harbor the potential to eventually translate this knowledge into specific screening and management protocols. Future projections for such mutations could even contribute to the emergence of molecular-based designer drugs developed through advances in genomics, proteomics, high-throughput screening, and bioinformatics, which would be effective therapeutically for these high-cancer risk patients.",
author = "Carlos Sarroca and P{\"a}ivi Peltom{\"a}ki and Nora Alfano and Gladys Tedesco and {Della Valle}, Adriana and Alejandra Dominguez and Lynch, {Henry T.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S0165-4608(02)00766-5",
language = "English",
volume = "142",
pages = "13--20",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Three new mutations in hereditary nonpolyposis colorectal cancer (Lynch syndrome II) in Uruguay

AU - Sarroca, Carlos

AU - Peltomäki, Päivi

AU - Alfano, Nora

AU - Tedesco, Gladys

AU - Della Valle, Adriana

AU - Dominguez, Alejandra

AU - Lynch, Henry T.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Hereditary nonpolyposis colorectal cancer (HNPCC) is the most common hereditary form of colorectal cancer (CRC). Our purpose is to describe three extended HNPCC families, each of which manifests novel germline mutations in Uruguay, a small country that is a study model for cancer investigation given its high cancer incidence and mortality rate. This is a study of three extended HNPCC families in which extensive genealogic information, medical history, and pathology findings are critically reviewed. DNA testing was performed for evidence of HNPCC mutations. The findings reveal three novel germline mutations, namely MLH1, with a deletion resulting in a frameshift and a premature stop codon (codon 228) in one of the families; in the second family, MSH2 exon 1, codon 61 at nucleotide 181, which results in immediate stop of translation; and in the third family, a mutation in MSH2 at exon 3: the amino acid at nucleotide 530, codon 117, causing a frameshift and a premature stop codon eight base pairs later. We conclude that it is important to study HNPCC mismatch repair genes because of emerging evidence for genotypic and phenotypic heterogeneity, which will harbor the potential to eventually translate this knowledge into specific screening and management protocols. Future projections for such mutations could even contribute to the emergence of molecular-based designer drugs developed through advances in genomics, proteomics, high-throughput screening, and bioinformatics, which would be effective therapeutically for these high-cancer risk patients.

AB - Hereditary nonpolyposis colorectal cancer (HNPCC) is the most common hereditary form of colorectal cancer (CRC). Our purpose is to describe three extended HNPCC families, each of which manifests novel germline mutations in Uruguay, a small country that is a study model for cancer investigation given its high cancer incidence and mortality rate. This is a study of three extended HNPCC families in which extensive genealogic information, medical history, and pathology findings are critically reviewed. DNA testing was performed for evidence of HNPCC mutations. The findings reveal three novel germline mutations, namely MLH1, with a deletion resulting in a frameshift and a premature stop codon (codon 228) in one of the families; in the second family, MSH2 exon 1, codon 61 at nucleotide 181, which results in immediate stop of translation; and in the third family, a mutation in MSH2 at exon 3: the amino acid at nucleotide 530, codon 117, causing a frameshift and a premature stop codon eight base pairs later. We conclude that it is important to study HNPCC mismatch repair genes because of emerging evidence for genotypic and phenotypic heterogeneity, which will harbor the potential to eventually translate this knowledge into specific screening and management protocols. Future projections for such mutations could even contribute to the emergence of molecular-based designer drugs developed through advances in genomics, proteomics, high-throughput screening, and bioinformatics, which would be effective therapeutically for these high-cancer risk patients.

UR - http://www.scopus.com/inward/record.url?scp=0344837402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344837402&partnerID=8YFLogxK

U2 - 10.1016/S0165-4608(02)00766-5

DO - 10.1016/S0165-4608(02)00766-5

M3 - Article

VL - 142

SP - 13

EP - 20

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 1

ER -